When bacteria transition from free-floating (planktonic) individuals to sessile communities, they construct a defensive fortress known as a biofilm. As reviewed by Ren et al., these structuralized microbial communities act as nearly impenetrable fortresses for chronic pathogens. The primary line of defense is not the bacterial cell wall itself, but rather the self-produced extracellular polymeric substance (EPS) matrix—a complex meshwork of polysaccharides, proteins, and extracellular DNA (eDNA) that acts as a physical and metabolic shield.
Traditional antibiotics are optimized to kill active, planktonic cells, but they frequently fail against biofilms because they cannot penetrate this dense matrix. Consequently, bacteria within biofilms can tolerate antimicrobial concentrations up to 1,000 times higher than their free-floating counterparts.
To overcome this barrier, a major research direction focuses on matrix disruption. Instead of attempting to blast through the fortress with higher antibiotic doses, researchers are developing strategies to dismantle, soften, or dissolve the EPS matrix itself. Once the structural integrity of the matrix is compromised, the embedded pathogens lose their protective shield and become highly vulnerable to standard antimicrobials and host immune clearance.
Starving the Scaffold: Inhibiting Matrix Assembly
A biofilm requires continuous synthesis of its structural components to maintain its architecture. One intuitive approach to matrix disruption is to shut down the genetic and molecular pathways responsible for producing this biological concrete.
Extracellular DNA (eDNA) is a critical structural scaffold that holds the biofilm matrix together. Liu et al. (2019) demonstrated that suppressing the agr quorum-sensing system downregulates the cidA gene, which is responsible for the release of eDNA. By reducing the availability of this adhesive component, the bacteria are forced to form a physically weaker, less dense biofilm architecture that is easily cleared.
Similarly, the protein and polysaccharide components of the matrix can be targeted. Wang et al. showed that certain antifibrinolytic agents can actively reduce the concentration of proteins and polysaccharides within the EPS. This structural disruption prevents bacteria from establishing a protective physical barrier on medical implants. At a macro-environmental level, Han et al. found that probiotic bacterial extracts can dismantle existing structures by directly interfering with the production and distribution of EPS and matrix proteins, rendering the community less adherent.
Enzymatic Softening and Phage Drills
Once a biofilm has matured, disrupting it requires breaking down established polymers. Because the matrix is highly dependent on its specific biochemical composition, it is uniquely susceptible to targeted enzymatic degradation. For example, Gao et al. demonstrated that microbial structures held together by a cellulose-based matrix can be completely abolished by cellulase enzymes, while remaining unaffected by protein-degrading enzymes.
[Intact Biofilm] ---> (Phage/Enzyme Treatment) ---> [Softened Matrix] ---> (Antibiotic/Disinfectant) ---> [Bacterial Clearance]
Dense EPS matrix Digests polysaccharides Increased porosity Penetrates deep layers Eradicates infection
blocks drugs & opens channels & permeability to reach dormant cells
Bacteriophages—viruses that infect bacteria—have evolved to use this vulnerability to their advantage. Rather than relying solely on cell lysis, many phages deploy matrix-degrading enzymes to pierce the biofilm shield. Hu et al. utilized a "phage-first" sequential treatment strategy to exploit this mechanism. The lytic cycle of the virus releases enzymes that physically weaken and soften the extracellular matrix. This process increases the porosity and permeability of the biofilm, allowing secondary chemical disinfectants (like chlorhexidine) to penetrate into the deepest layers of the bacterial community.
This enzymatic degradation pathway, also highlighted by Kim (2023) and Yan et al., offers a non-antibiotic method to strip away protective polysaccharide shields, exposing the hidden pathogens underneath.
Physicochemical Disruption via Surfactants and Energy
Beyond biochemical targeting, the physical integrity of the EPS matrix can be disrupted using chemical wedges or localized energy.
Surfactants are highly effective at destabilizing the hydrophobic and hydrophilic interactions that stabilize the EPS matrix. Cheng et al. demonstrated that incorporating surfactants into nanoemulsion formulations allows active antimicrobial agents to rapidly penetrate dense methicillin-resistant Staphylococcus aureus (MRSA) biofilms. Instead of applying an external surfactant, Li (2022) discovered that the antimicrobial peptide CRAMP triggers an internal "molecular eject button" in Pseudomonas aeruginosa. It forces a metabolic shift that downregulates EPS production while upregulating the bacteria's own biological surfactants, chemically dissolving the biofilm from the inside out and forcing cell detachment.
Alternatively, light and heat can be used to physically loosen the matrix:
- Thermo-Chemical Disruption: As reviewed by Wu (2024), photothermal therapy uses localized heating to physically loosen the dense extracellular matrix. This thermal expansion increases molecular diffusion, dramatically improving the penetration and efficacy of co-administered oxidative agents.
- Photodynamic Disruption: Zhang et al. and Li et al. (2022) showed that photodynamic therapy generates reactive oxygen species that simultaneously damage bacterial membranes and downregulate the genes responsible for maintaining biofilm structural integrity.
Overcoming the Eradication Threshold
The ultimate goal of matrix disruption is to lower the Minimum Biofilm Eradication Concentration (MBEC)—the dauntingly high drug concentration required to clear a sessile infection.
She et al. demonstrated that combining redox-disrupting adjuvants with standard antibiotics can lower the MBEC by over eight-fold. By neutralizing the physical and metabolic shields of the biofilm, the adjuvant allows conventional antibiotics to reach and kill bacteria that would otherwise be completely protected. This dual action—preventing initial attachment while actively dismantling pre-formed, mature structures—is a recurring theme in the evaluation of novel natural compounds like methylaervine (Liu et al., 2024), cinnamaldehyde (Zhu et al., 2025), and marine probiotics (Liu et al., 2025).
This paradigm shift has led to the engineering of biofilm-selective antimicrobials. While standard antibiotics are less effective against biofilms than free cells, specialized peptides display the exact opposite profile. Work by Silva et al., Alves (2016), and the authors of the polar fish peptide study highlights synthetic peptides designed with a high affinity for matrix polymers. These molecules achieve a lower minimum inhibitory concentration against structured biofilms than against free-swimming cells. They are optimized to exploit the physical properties of the matrix shield, turning the biofilm's own protective architecture into an entry point for targeted destruction.
Key Foundational Work
Periodontal therapy by local delivery of minocycline. Clinical study of periodontal therapy by LS-007. (1988) — contributed 1 concept elements to this direction.
Anti-Biofilm and Immunomodulatory Activities of Peptides That Inhibit Biofilms Formed by Pathogens Isolated from Cystic Fibrosis Patients (2014) — contributed 1 concept elements to this direction.